Immune checkpoint inhibitors (ICIs), either as monotherapy (ICI-Mono) or combined with chemotherapy (ICI-Chemo), improves survival in advanced non-small cell lung cancer (NSCLC). However, prospective guidance for choosing between these options remain...
BACKGROUND: PD-1/PD-L1 immunotherapy represents the primary treatment for advanced NSCLC patients; however, response rates to this therapy vary among individuals. This dual-center study aimed to integrate habitat radiomics and multi-instance deep lea...
Hypoxia arises in most solid tumors with insufficient blood flow, which hinders the delivery and efficacy of therapeutic agents to tumors. In this work, utilizing anaerobic bacteria capable of seeking out hypoxic areas for flourishing, we constructed...
Programmed death-ligand 1 (PD-L1) is an important biomarker increasingly used as a predictive marker in breast cancer immunotherapy. Immunohistochemical quantification remains the standard method for assessment. However, it presents challenges relate...
Radiomics refers to the utilization of automated or semi-automated techniques to extract and analyze numerous quantitative features from medical images, such as computerized tomography (CT) or magnetic resonance imaging (MRI) scans. This study aims t...
AIM: To develop a positron emission tomography/computed tomography (PET/CT)-based radiomics model for predicting programmed cell death ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) patients and estimating progression-free survival...
The growing application of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has underscored the critical need for reliable methods to identify patient populations likely to respond to ICI treatments, particularly in lung cancer treatment. ...
Cancer imaging : the official publication of the International Cancer Imaging Society
Mar 12, 2025
BACKGROUND: Programmed death ligand 1 (PD-L1) expression status, closely related to immunotherapy outcomes, is a reliable biomarker for screening patients who may benefit from immunotherapy. Here, we developed and validated an interpretable machine l...
Although the immune checkpoint inhibitors (ICIs) have demonstrated remarkable anti-tumor efficacy in solid tumors, the proportion of ESCC patients who benefit from ICIs remains limited. Current biomarkers have assisted in identifying potential respon...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.